A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
What is the purpose of this trial?
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Ages18 years and older
- GenderFemale only
- Trial withRegeneron Pharmaceuticals, Inc.
- Start Date03/29/2022
- End Date10/22/2024
- Last Updated04/01/2022
- Study HIC#2000029247